Spencer Breithaupt Joins PetVivo Holdings, Inc. Board of Directors
April 14 2023 - 12:35PM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company")
an emerging biomedical device company focused on the
commercialization of innovative medical therapeutics for companion
animals and animal athletes is pleased to announce that Spencer
Breithaupt has joined the Company’s Board of Directors.
"We are thrilled to welcome Spencer to PetVivo’s
Board of Directors” said John Lai, Chief Executive Officer of
PetVivo Holdings, Inc. “Spencer brings a wealth of industry and
business experience to our Company. We anticipate that his addition
to the board will provide us with the knowledge and expertise that
will guide our Company to attain the resources and industry
relationships necessary for success."
Mr. Breithaupt brings over 30 years of
management and leadership experience in the animal health industry,
most recently with MWI Animal Health, Amerisource Bergen where he
held numerous positions on the executive leadership team. Mr.
Breithaupt did account segmentation allowing MWI to expand from a
regional player to the largest US nationwide animal health
distributor by expanding the sales force along with developing the
corporate account team, restructuring and revitalizing the equine
team and re-shaping the telesales team. Mr. Breithaupt spent his
career working for Fortune 500 animal health companies - Bristol
Myers, Johnson & Johnson and Wyeth - where he held various
sales and marketing roles. At Wyeth/Fort Dodge Animal Health, he
developed a distributor strategy and implemented the first MAP
pricing model into the animal health industry. He has also served
as the Chairman of the Animal Health Corridor; the Corridor brings
the global animal health industry together around shared priorities
with the goal of working collaboratively and speaking with one
voice to advance the industry. Growing up in the veterinarian
industry as the son of a prominent veterinarian, gave him great
insight when launching his career into animal health. Mr.
Breithaupt has seen the transformation of the animal-human bond,
and it continues to make him passionate about improving the lives
of our pets.
“I am extremely excited to be joining such an
innovative company with beneficial technology that has the
capability of enhancing the lives of animals and their owners.”
said Spencer Breithaupt. “With each of my meetings with management
and members of the Board of Directors, I believe that PetVivo is
ready to launch to new heights and believe I can make valuable
contributions on their Board. I am thrilled to be appointed to the
PetVivo Board of Directors and can’t wait to get to work with these
visionary company leaders.”
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an
emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of nineteen
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG™
with OsteoCushion™ technology, a veterinarian-administered,
intraarticular injection for the management of lameness and other
joint related afflictions, including osteoarthritis, in dogs and
horses, is currently available for commercial sale.
For more information about PetVivo Holdings,
Inc. and our revolutionary product, Spryng with OsteoCushion
Technology, please contact info1@petvivo.com or visit
https://petvivo.com/
CONTACT:
John Lai, CEOPetVivo Holdings, Inc.Email:
info1@petvivo.com (952) 405-6216
Forward-Looking commercial Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements are
based on information currently available to the Company and its
current plans or expectations and are subject to a number of
uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2022 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jun 2024 to Jul 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2023 to Jul 2024